KRBP vs. TCBP, FNCH, ALBT, ELOX, TCON, GMDAQ, WINT, FRTX, NSTGQ, and PALI
Should you be buying Kiromic BioPharma stock or one of its competitors? The main competitors of Kiromic BioPharma include TC Biopharm (TCBP), Finch Therapeutics Group (FNCH), Avalon GloboCare (ALBT), Eloxx Pharmaceuticals (ELOX), TRACON Pharmaceuticals (TCON), Gamida Cell (GMDAQ), Windtree Therapeutics (WINT), Fresh Tracks Therapeutics (FRTX), NanoString Technologies (NSTGQ), and Palisade Bio (PALI). These companies are all part of the "biological products, except diagnostic" industry.
TC Biopharm (NASDAQ:TCBP) and Kiromic BioPharma (NASDAQ:KRBP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, community ranking, media sentiment and profitability.
TC Biopharm has higher revenue and earnings than Kiromic BioPharma.
TC Biopharm has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Kiromic BioPharma has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500.
TC Biopharm and Kiromic BioPharma both received 1 outperform votes by MarketBeat users.
In the previous week, Kiromic BioPharma had 1 more articles in the media than TC Biopharm. MarketBeat recorded 3 mentions for Kiromic BioPharma and 2 mentions for TC Biopharm. Kiromic BioPharma's average media sentiment score of 0.54 beat TC Biopharm's score of 0.49 indicating that TC Biopharm is being referred to more favorably in the media.
16.3% of TC Biopharm shares are owned by institutional investors. Comparatively, 10.9% of Kiromic BioPharma shares are owned by institutional investors. 0.1% of TC Biopharm shares are owned by company insiders. Comparatively, 3.3% of Kiromic BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
TC Biopharm beats Kiromic BioPharma on 5 of the 8 factors compared between the two stocks.
Get Kiromic BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kiromic BioPharma Competitors List
Related Companies and Tools
